Low-density lipoprotein cholesterol levels are positively associated with the risk of endobronchial biopsy-induced refractory hemorrhage in patients with lung cancer

Table 2 Multivariate regression analysis of LDL-C and the risk of EBB-induced refractory hemorrhage

Parameter	Crude OR (95% CI) p-value	Model I OR (95% CI) p-value	Model II OR (95% CI) p-value
LDL-C (mmol/L)	1.24 (0.93, 1.65) 0.1437	1.48 (1.08, 2.02) 0.0142	2.65 (1.40, 5.00) 0.0026
Quartile of LDL-C (mmol/L)
Q1 (< 2.26)	Ref.	Ref.	Ref.
Q2 (2.26–2.75)	1.81 (0.93, 3.55) 0.0830	2.01 (1.01, 4.01) 0.0465	2.32 (1.07, 5.03) 0.0327
Q3 (2.76–3.28)	1.57 (0.78, 3.13) 0.2031	1.82 (0.89, 3.71) 0.1011	2.37 (0.94, 5.95) 0.0665
Q4 (> 3..28)	1.73 (0.88, 3.41) 0.1110	2.48 (1.21, 5.07) 0.0128	3.65 (1.16, 11.51) 0.0270
P for trend	0.2013	0.0259	0.0464

Model I adjusts for location of the lesion, histological types, stage of cancer, HDL-C, and apolipoprotein E. Model II adjusts for gender, location of the lesion, histological type, smoking, SBP, hemoglobin, neutrophil percentage, PT, APTT, CRP, ALT, triglyceride, HDL-C, apolipoprotein B, and apolipoprotein E. LDL-C, low-density lipoprotein cholesterol; EBB endobronchial biopsy; SBP, systolic blood pressure; PT, prothrombin time; APTT, activated partial thromboplastin time; CRP, C-reactive protein; ALT, alanine aminotransferase; HDL-C, high-density lipoprotein cholesterol